U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H22F3N
Molecular Weight 357.412
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CINACALCET

SMILES

C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C2=CC=CC3=CC=CC=C23

InChI

InChIKey=VDHAWDNDOKGFTD-MRXNPFEDSA-N
InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H22F3N
Molecular Weight 357.412
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Cinacalcet is a positive allosteric modulator of calcium sensing receptor. The drug is approved by FDA (Sensipar trade name) and used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis; hypercalcemia in adult patients with parathyroid carcinoma; hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SENSIPAR
Primary
SENSIPAR

Cmax

ValueDoseCo-administeredAnalytePopulation
29.9 ng/mL
90 mg single, oral
CINACALCET blood
Homo sapiens
26.6 ng/mL
75 mg single, oral
CINACALCET plasma
Homo sapiens
20.6 ng/mL
75 mg single, oral
CINACALCET plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
323 ng × h/mL
90 mg single, oral
CINACALCET blood
Homo sapiens
296 ng × h/mL
75 mg single, oral
CINACALCET plasma
Homo sapiens
346 ng × h/mL
75 mg single, oral
CINACALCET plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
12.4 h
90 mg single, oral
CINACALCET blood
Homo sapiens
30.4 h
75 mg single, oral
CINACALCET plasma
Homo sapiens
33.6 h
75 mg single, oral
CINACALCET plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Secondary HPT in patients with CKD on dialysis: starting dose is 30 mg once daily. Hypercalcemia: starting dose is 30 mg twice daily.
Route of Administration: Oral
In Vitro Use Guide
Cinacalcet (100 nM) suppressed parathyroid hormone secretion in human parathyroid cells.
Substance Class Chemical
Record UNII
UAZ6V7728S
Record Status Validated (UNII)
Record Version